In recent days, we’ve had 10 stories that shook the world. The players are so big, the technologies so ambitious, the scale so huge and the risks in some cases so high — we’ve grouped them together into one Big Story. These are ‘Quakers, as in earthquakes. 1. ExxonMobil expands interest in biofuels, acquires stake […]
In California, Amyris, Inc. completed a previously announced joint venture agreement with MF 92 VENTURES LLC, a Minerva Foods subsidiary, to develop molecules for the sustainable production and distribution of animal protein. Minerva and Amyris will collaborate on the development, scale-up and production of new target molecules, which Minerva will fund and bring to market […]
In California, Amyris, Inc. has closed its offering of 1.50% convertible senior notes due 2026 for gross proceeds of $690.0 million. The proceeds include the full exercise of the $90.0 million option granted by Amyris to the initial purchasers of the notes. The notes were offered and sold in a private placement to persons reasonably believed […]
Delivering on the promise of synthetic biology, her’s the latest view on products and technology from the “No Compromise Crew” at Amyris.
Amyris shared this illuminating slide guide with investors and now you can check it out too. From their thoughts on the bio-revolution, their mission, their lab-to-market proprietary system, ingredients pipeline, consumer brands, and how they are changing the global beauty and personal care market one ingredient at a time, this is one slide guide you […]
In this morning’s Digest (September 10th) round-up of activities announced on advances in the production of sustainable aviation fuels, we reported on an announce by Amyris and Total regarding future production of farnesene-based jet fuel, in which we picked up a storyline from all the way back in 2014 and reported what was true then, […]
In California, Amyris, Inc. achieved promising in-vivo results in a study of its licensed RNA vaccine through intranasal delivery, developed in collaboration with the Infectious Disease Research Institute (IDRI), which means an effective Covid-19 nose spray vaccine could become reality. In-vivo results indicate that, when delivered to the mucosal membranes via intranasal administration, the Amyris/IDRI […]
In California, Amyris, Inc. reports another record quarter of underlying revenue, another record quarter of consumer revenue and significant gross margin expansion, and a strong cash position and robust outlook into second half 2021. “With Q2 we completed another quarter of strong strategic and operational execution,” said John Melo, President and Chief Executive Officer. “We […]
In California, Amyris, Inc. signed an exclusive license with Nant Africa, LLC relating to the development and use of the RNA COVID vaccine Amyris developed in coordination with the Infectious Disease Research Institute (IDRI). Amyris’ partnership with Nant Africa is of significant value to Amyris as it provides the fastest path to market for the […]
Just a few weeks ago, Amyris shared this illuminating slide guide at their investor virtual min-series. Now here’s your chance to see what they had to say about their ingredients platform, yeast strains, scaling up, and how synthetic biology is capable of remaking most of the world’s chemistry.
